102 related articles for article (PubMed ID: 3801269)
1. Potentiation of RSU-1069 tumour cytotoxicity by 5-hydroxytryptamine (5-HT).
Chaplin DJ
Br J Cancer; 1986 Nov; 54(5):727-31. PubMed ID: 3801269
[TBL] [Abstract][Full Text] [Related]
2. The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain.
Chaplin DJ; Acker B
Int J Radiat Oncol Biol Phys; 1987 Apr; 13(4):579-85. PubMed ID: 3558048
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and cytotoxicity of RSU-1069 in subcutaneous 9L tumours under oxic and hypoxic conditions.
Wong KH; Koch CJ; Wallen CA; Wheeler KT
Br J Cancer; 1991 Apr; 63(4):484-8. PubMed ID: 2021530
[TBL] [Abstract][Full Text] [Related]
4. RSU 1069, a 2-nitroimidazole containing an alkylating group: high efficiency as a radio- and chemosensitizer in vitro and in vivo.
Adams GE; Ahmed I; Sheldon PW; Stratford IJ
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1653-6. PubMed ID: 6548211
[TBL] [Abstract][Full Text] [Related]
5. The chemosensitizing and cytotoxic effects of RSU 1164 and RSU 1165 in a murine tumor model.
Siemann DW
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1115-8. PubMed ID: 2703392
[TBL] [Abstract][Full Text] [Related]
6. Studies of the in vivo and in vitro cytotoxicity of the drug RSU-1069.
Hill RP; Gulyas S; Whitmore GF
Br J Cancer; 1986 Jun; 53(6):743-51. PubMed ID: 3755053
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
Binger M; Workman P
Cancer Chemother Pharmacol; 1991; 29(1):37-47. PubMed ID: 1742848
[TBL] [Abstract][Full Text] [Related]
8. Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas.
Cole S; Stratford IJ; Adams GE; Fielden EM; Jenkins TC
Radiat Res; 1990 Oct; 124(1 Suppl):S38-43. PubMed ID: 2236508
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of cyclophosphamide cytotoxicity in vivo: a study with misonidazole and fifteen other 1-substituted 2-nitroimidazoles.
Chaplin DJ; Sheldon PW; Ahmed I; Adams GE
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1647-51. PubMed ID: 6480452
[TBL] [Abstract][Full Text] [Related]
10. Bioreduction of RSU 1069 and mitomycin C after dearterialization.
Wang LQ; Persson BG; Bengmark S
Eur J Surg Oncol; 1993 Oct; 19(5):455-62. PubMed ID: 8405482
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of melphalan activity in the KHT sarcoma by the radiosensitizer RSU 1069.
Siemann DW; Maddison K; Wolf K
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1657-60. PubMed ID: 6548212
[TBL] [Abstract][Full Text] [Related]
12. Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo.
Adams GE; Ahmed I; Sheldon PW; Stratford IJ
Br J Cancer; 1984 May; 49(5):571-7. PubMed ID: 6547051
[TBL] [Abstract][Full Text] [Related]
13. Postirradiation modification of tumor blood flow: a method to increase the effectiveness of chemical radiosensitizers.
Chaplin DJ
Radiat Res; 1988 Aug; 115(2):292-302. PubMed ID: 3406369
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of the antitumor efficacy of lomustine by the radiosensitizer RSU 1069.
Siemann DW; Alliet K; Maddison K; Wolf K
Cancer Treat Rep; 1985 Dec; 69(12):1409-14. PubMed ID: 3841024
[TBL] [Abstract][Full Text] [Related]
15. Enhanced cell killing in lewis lung carcinoma and a human pancreatic-carcinoma xenograft by the combination of cytotoxic drugs and misonidazole.
Stephens TC; Courtenay VD; Mills J; Peacock JH; Rose CM; Spooner D
Br J Cancer; 1981 Apr; 43(4):451-7. PubMed ID: 7236488
[TBL] [Abstract][Full Text] [Related]
16. The radiosensitizing and toxic effects of RSU-1069 on hypoxic cells in a murine tumor.
Chaplin DJ; Durand RE; Stratford IJ; Jenkins TC
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1091-5. PubMed ID: 3755714
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of alkylating chemotherapy by dual function nitrofurans in multi-cell spheroids and solid tumors.
Siemann DW; Sutherland RM
Radiother Oncol; 1992 Aug; 24(4):239-45. PubMed ID: 1410579
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxicity of RSU 1069 in spheroids and murine tumors.
Olive PL; Durand RE; Chaplin DJ
Int J Radiat Oncol Biol Phys; 1987 Sep; 13(9):1361-6. PubMed ID: 3624045
[TBL] [Abstract][Full Text] [Related]
19. The differential cytotoxicity of RSU 1069: cell survival studies indicating interaction with DNA as a possible mode of action.
Stratford IJ; Walling JM; Silver AR
Br J Cancer; 1986 Mar; 53(3):339-44. PubMed ID: 3754453
[TBL] [Abstract][Full Text] [Related]
20. Synergistic enhancement of the efficacy of the bioreductively activated alkylating agent RSU-1164 in the treatment of prostatic cancer by photodynamic therapy.
Henry JM; Isaacs JT
J Urol; 1989 Jul; 142(1):165-70. PubMed ID: 2733098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
